Researchers Identified HERC4 as TNF Cell Death Switch
A newly discovered protein regulation mechanism could enable more precise treatments for chronic inflammation.
Updated on Sept. 28, 2026 in Life Sciences
Live Poll
Do you believe current medical research is effectively producing new, accessible treatments for chronic inflammatory diseases?
An international research team has identified the HERC4 protein as the critical switch that shifts TNF signaling from survival to cell death. Published in Nature Structural and Molecular Biology, these findings clarify the molecular mechanism behind TNF-mediated inflammation.
Why it matters
Understanding this signaling switch provides a new target for treating chronic inflammatory conditions that have relied on general TNF inhibitors for three decades. By identifying HERC4 as the mediator, researchers may be able to develop therapies with a broader spectrum of activity than current standards.
HERC4 acts as an E3 ubiquitin ligase, an enzyme that adds ubiquitin proteins to target molecules to initiate the formation of Complex II. This process ubiquitinates kinase-active RIPK1, effectively transitioning the protein from a survival signal to a death-triggering signal.
The players
University of Cologne
A German research institution focused on advanced molecular biology and inflammation studies.
National Institute of Biological Sciences
A Beijing-based research center specializing in cellular signaling pathways and disease mechanisms.
The details
Researchers utilized a knockout screen, a method that disables individual genes to observe their function, to pinpoint proteins involved in RIPK1 ubiquitination. The study found that HERC4 binds directly to RIPK1 to initiate the formation of Complex II, a protein assembly that drives either apoptosis (programmed cell death) or necroptosis (inflammatory cell death). In mouse models, those lacking HERC4 showed significant protection against TNF-induced systemic inflammatory responses and acute liver damage.
Timeline
September 28, 2026: Research findings were published in Nature Structural and Molecular Biology.
The Tech Race
Current inflammation therapies have centered on broad TNF inhibitors for three decades, but they often lack selectivity. The identification of HERC4 marks a significant shift in the competitive landscape, potentially offering a more precise pathway for clinical intervention than established methods.
This development is currently in the research stage and does not impact existing treatments or patient workflows yet. Future clinical benefits depend on the successful development and regulatory approval of oral HERC4 inhibitors.
The takeaway
The discovery of the HERC4 switch transforms our understanding of how inflammatory signaling transitions from survival to death. Researchers are now prioritizing the development of oral inhibitors that could provide more targeted alternatives to traditional systemic TNF-blocking drugs.
What happens next
The research team plans to develop low-molecular-weight HERC4 inhibitors intended for oral administration.
Further reading
For more on the latest research in this field, visit Life Sciences.
More information
Read the complete Nature Structural and Molecular Biology publication for technical details.
Source note: This article includes information reported by Informationdienst Wissenschaft e.V. - idw.
Live Poll
Do you believe current medical research is effectively producing new, accessible treatments for chronic inflammatory diseases?
